Result card

  • CUR8: How many people belong to the target population?

How many people belong to the target population?

Authors: Antonio Migliore, Tapani Keranen, Sinikka Sihvo

Internal reviewers: Kristian Lampe

The worldwide prevalence estimates are given usually for dementia than for Alzheimer’s disease since the possibilities to make correct diagnosis can vary. Also estimates vary between studies.

The age-standardised prevalence of dementia among populations > 60 years is 5-7% {65}. In 2010 it was estimated that there are over 35 million people worldwide living with dementia. These numbers are expected to double every 20 years to 65.7 million in 2030 and to 115.4 million in 2050 {65} {Table CUR-5}. In 2010 over half (58%) of people with dementia lived in low or middle income countries, this proportion is expected to rise to 71% in 2050. China has more cases of Alzheimer’s disease than any other country; in 2010 there were 919 million (95% CI 5.92–12.48) people with dementia and the prevalence was 2.6% (0.0–28.2) at age 60-65 years and 60.5% (39.7–81.3) at age 95-99 year olds {12}. The incidence of dementia in China was 9.87 per 1000 person-years and that of Alzheimer’s disease 6.25/1000 person-years {12}. The increase in numbers of people with dementia will occur much rapidly in low or middle income countries and faster than assumed {12} {84}.

According to worldwide meta-analysis of studies between 1984-2008, the prevalence of mild cognitive impairment was 24.6% but varied between 21.5–71.5%, and the prevalence of amnestic MCI (aMCI) alone was 4.6% (range 8.5–25.9%). For people > 65 years the MCI incidence varied between 21.5–71.3/1000 person-years. For aMCI the rates ranged from 8.5 to 25.9 per 1000 person-years {81}. In another systematic review the incidence rates were 51–76.8/1000 person-years and for aMCI between 9.9 and 40.6/1000 person-years {48}.

Migliore A et al. Result Card CUR8 In: Migliore A et al. Health Problem and Current Use of the Technology In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 October 2020]. Available from: